Background: Large health care databases are increasingly used to examine the dissemination and benefits and harms of chemotherapy treatment in routine practice, particularly among patients excluded from trials (eg, the elderly). Misclassification of chemotherapy could bias estimates of frequency and association, warranting an updated assessment.
C hemotherapy represents an integral part of the treatment plan for many individuals diagnosed with cancer, as it decreases the risk of recurrence and mortality in many settings. Randomized controlled trials have documented the efficacy of chemotherapeutic agents used to treat a variety of cancers. To examine the translation of this evidence into the routine clinical setting, large health care databases, such as the Surveillance, Epidemiology, and End Results (SEER) program-Medicare-linked database, are increasingly used to conduct nonexperimental studies evaluating the uses, benefits, and harms of these treatments among individuals excluded from trials, including older adults, those with multiple comorbidities, and those treated off-label. The validity of these studies relies upon a variety of issues, including the ability of claims data to accurately capture treatment(s) of interest, study endpoint(s), and other important design and clinical issues. 27 Measurement error in the assessment of chemotherapy could lead to biased study results. Prior research supports the validity of claims data to identify intravenously administered chemotherapy treatment for a variety of cancer sites, [28] [29] [30] [31] [32] but does not address more recently approved or orally administered agents, or changes in validity using multiple claims windows following diagnosis.
We conducted a validation study to assess the utility of Medicare claims for capturing the receipt of any chemotherapy and specific agents delivered to patients diagnosed at age Z65 with stage II or III colorectal cancer (CRC), in situ or early-stage breast, non-small cell lung cancer (NSCLC), or ovarian cancer. This assessment (1) evaluated the validity of selected singleagent chemotherapies, including an orally administered agent; and (2) described the variation in measures of validity for any chemotherapy and specific treatments over multiple follow-up periods and across cancer sites.
METHODS

Data Sources
We used the National Cancer Institute's (NCI) data from the Patterns of Care studies (POC) as the gold standard and the linked SEER-Medicare data as the test source for identifying chemotherapy. The SEER program of cancer registries collects demographic information, clinical and tumor characteristics, vital status, and cause of death for all incident cancers reported for individuals who reside in one of the registries' defined geographic areas. 33 NCI supplements the standard SEER registry abstraction to obtain detailed information about treatment for a subset of SEER cases. This effort, known as the POC, was developed by NCI to investigate the dissemination of state-of-the-art cancer treatment into community practices. These studies selected a stratified random sample of individuals (proportionate registry size) from the SEER program 10, 12, and 13 cancer registries which covered up to 14% of the US population. 34 All individuals were aged Z20 years with a histologically confirmed cancer for selected sites, stages, and years. A listing of all cancers and stages examined by the POC are detailed elsewhere. 35 Patients were excluded if the cancer diagnosis was determined at autopsy or on the death certificate; the diagnosis was a second malignancy other than to a nonmelanoma skin cancer; or if the individual was simultaneously diagnosed with another cancer. Individuals were sampled by sex with oversampling of African Americans and Hispanics in all years and Asian/Pacific Islanders and American Indians/Alaskan Natives in 2005 only.
In addition to the standard SEER abstraction, the POC studies supplemented information on initial course of treatment by asking physicians (through mailed questionnaire) to verify the treatments delivered to patients; reviewing a unified medical record (inpatient and outpatient); and in some cases SEER registrars visited doctors' offices to abstract data. Requested information included whether radiation, chemotherapy, or immunotherapy was received as part of the initial course of treatment, identifying the specific agents delivered and the dates of first administration (2005 studies only).
The SEER-Medicare data arise from a linkage of persons in the SEER data with their Medicare enrollment, part A (Hospital insurance) and B (Medical insurance) claims data. These data include approximately 3.3 million elderly individuals (age Z65) diagnosed with cancer in one of the SEER areas or regions. 36 Approximately 94% of all elderly individuals included in SEER have been matched to the Medicare enrollment file with an established matching algorithm. Virtually 100% of all beneficiaries are eligible for Part A and 93% will opt to enroll in part B. 37 For Medicare-eligible individuals with fee-for-service coverage, Medicare claims are organized into files including claims for inpatient hospitalizations, durable medical equipment (DME), outpatient hospital services, and physician and other provider services. 32 These claims encompass a multitude of information on specific service dates, diagnoses, procedures, and agents delivered during medical encounters using various medical coding systems. Diagnoses and procedures on hospital claims are reported using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) codes. ICD-9 CM diagnosis and procedure codes can be used to identify chemotherapy administration, but not specific agents. DME claims contain National Drug Codes (NDCs) that can be used to identify specific oral chemotherapeutic agents that are equivalent to other Medicare-covered intravenously administered chemotherapy agents. 38 Physician and outpatient claims include ICD-9 CM diagnosis codes and Healthcare Common Procedure Coding System (HCPCS) codes. HCPCS can be used to identify chemotherapy and specific agents. Outpatient claims include revenue center codes that serve as another means of identifying chemotherapy administration. The codes used in our analysis are presented in the Appendix (Supplemental Digital Content 1, http://links.lww.com/MLR/A255).
Study Sample and Eligibility Criteria
The cancer sites, stages, and years of diagnoses were selected based on availability of the POC data and included in situ or early-stage breast cancer diagnosed in 2000 and 2005, stage II or III CRC in 2000 and 2005, NSCLC in 2005, and ovarian cancer in 2002. All POC patients were required to be age Z65 years at cancer diagnosis; and have POC treatment information verified through physician confirmation or a unified medical record review. Patients identified as being enrolled in a clinical trial were excluded because Medicare only covers routine costs associated with federally funded clinical trials (eg, office visits and medical tests), and may not cover the cost of the agents themselves. 39 This study included eligible patients in the POC data who were matched to the SEER-Medicare data. Using the Medicare files, we required that all individuals were continuously enrolled in Medicare Parts A and B for the 2-, 4-, 6-, 8-, 10-, or 12-month periods following diagnosis (the postdiagnosis periods); were never enrolled in a health maintenance organization during the associated postdiagnosis periods; did not have a subsequent cancer diagnosis (as reported by SEER) in the year following the qualifying POC cancer diagnosis; and had at least 1 Medicare claim during the specified postdiagnosis period. These criteria ensured that detailed claims for all individuals in the study were reported to Medicare and were not attributable to the treatment of a subsequent cancer. Because of the timevarying nature of these criteria, the number of individuals eligible for analysis in each postdiagnosis period decreased over time. Details of the 6-month post-diagnosis cohort exclusions are listed in the Appendix (Supplemental Digital Content 2, http://links.lww.com/MLR/A256).
Identification of Receipt of Chemotherapy and Specific Agents in POC and SEER-Medicare
For this analysis, the POC cohort was considered the gold standard measure for the receipt of any chemotherapy and for specific agents. Individuals were defined in POC as receiving any chemotherapy if a physician verified or a unified medical record identified that the individual was administered any chemotherapeutic agent. The receipt of specific agents was identified in POC through the same mechanism. For the POC studies conducted in 2005, the date of first administration was collected for each specific agent delivered. Therefore, the analysis defined the initial course of treatment as the diagnosis date (set to the first day of the month, as only month of diagnosis is reported by SEER) to 365 days after the diagnosis date. If treatment was received outside of the year following diagnosis, it was not considered part of the initial course of chemotherapy.
Identifying the receipt of any chemotherapy and specific agents in Medicare claims required an examination of multiple claims files and their associated diagnosis, procedure, and drug codes and service dates. If a claim for a general chemotherapy procedure code, a diagnosis code for chemotherapy administration, or HCPCS code or NDC for a specific agent was found, the individual was defined as having received chemotherapy during the specified postdiagnosis period. The receipt of specific chemotherapy agents were defined similarly by identifying at least 1 claim with a HCPCS code or NDC for the specific agent during the postdiagnosis period.
Comparison of Chemotherapy Reported in POC and SEER-Medicare
Reporting of the agreement between the 2 data sources and the validity of chemotherapy captured in Medicare claims was examined at interval periods using the 2-, 4-, 6-, 8-, 10-, and 12-month postdiagnosis cohorts. Specifically, we estimated the k and corresponding 95% confidence intervals (CIs) to assess concordance between the 2 data sources, as well as the sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) and their corresponding 95% CIs of the Medicare claims definitions using the POC as the gold standard.
We selected the specific chemotherapeutic agents to be validated based on their frequency of use in the 6-month postdiagnosis period. Using sample size calculations, we maximized the accuracy of the Se and Sp estimates to have a minimal acceptable lower confidence limit that is <10% from the point estimate. 40 Based upon this sample size calculation, we included only specific chemotherapeutic agents where the POC reported that there were 37 or more individuals receiving the treatment. Because of the small number of in situ and early-stage breast cancer patients receiving chemotherapy, the 2000 and 2005 POC data were combined for analysis.
Although the POC studies were considered the gold standard, they may be subject to measurement error in their reporting of initial chemotherapy treatment. Therefore, beyond reporting the k to assess concordance between the 2 sources, we also conducted a sensitivity analysis to examine the impact of potential misclassification of the gold standard (ie, the POC), 41 focusing on an example of oxaliplatin receipt among stage II or III CRC patients diagnosed in 2005.
All analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC). This study was reviewed by the University of North Carolina at Chapel Hill Institutional Review Board and was determined to be exempt from (IRB) approval. Figure 1 displays the sources of chemotherapy claims found in the Medicare files (hospital, physician, outpatient, DME, or multiple files) for all individuals included in the validation studies by cancer site and year of diagnosis. The large majority of individuals receiving chemotherapy only had claims reported in the physician file with very few individuals having claims identified in the hospital file only (<3%). However, variation by cancer site and year of diagnosis was evident, reflecting different settings in which treatment was delivered by site and over time. For example, the approval of capecitabine in 2005 for CRC increased the percentage of individuals with claims identified using the DME file in 2005, as bills for orally administered agents appear primarily in the DME file. Chemotherapy claims for breast cancer were largely identified by physician claims in both 2000 and 2005.
RESULTS
The comparisons of any chemotherapy identified by the POC and Medicare claims for the postdiagnosis periods for each cancer site/year are reported in Table 2 . Individuals receiving chemotherapy according to each data source is reported. Overall, the measures of agreement and validity for identifying the receipt of any chemotherapy were high for all cancer sites and postdiagnosis periods, except for the 2-and 4-month periods. Excluding those periods, k estimates of concordance ranged from 77% to 87%; Se ranged from 84% to 97%, Sp ranged from 78% to 97%, PPVs ranged from 87% to 96%, and NPVs ranged from 81% to 96%. The Sp estimates for the receipt of any chemotherapy for women diagnosed with ovarian cancer in 2002 were low in the later postdiagnosis periods. Because of the small number of women not receiving chemotherapy in the later postdiagnosis periods, the Sp estimates are unstable. Although the CIs are wide, these intervals include Sp ranges that are consistent with estimates across other cancer sites. Across all cancer sites and year, the Sp and Se estimates for the receipt of any chemotherapy did not vary by patient characteristics (data not shown). Table 3 describes the measures of agreement and validity for the Medicare claims definitions used to identify the receipt of specific chemotherapeutic agents during the 6month postdiagnosis period. For all intravenous agents administered to patients diagnosed with CRC and NSCLC, the measures of concordance and validity were high: k ranged from 71% to 95%; Se ranged from 75% to 95%; Sp ranged from 90% to 99%; PPV ranged from 85% to 99%; and NPV ranged from 81% to 97%. Consistently, these measures (k, Se, and PPV) were lowest for oxaliplatin. The measures of agreement and validity for identifying capecitabine, an orally administered agent equivalent to the intravenously administered 5-fluorouracil for CRC, in Medicare claims was poor with k and Se of only 55% and 47%, respectively.
For breast cancer, the Se estimates for cyclophosphamide and doxorubicin were lower than other cancer site agents at 75% and 73%, respectively; however, the 95% CIs included values consistent with other sites. For ovarian cancer, the Sp estimates for carboplatin and paclitaxel were low at 78% and 74%, respectively. The Sp estimates for the specific ovarian cancer agents were lower than agents used to treat other cancer sites across all postdiagnosis periods (data not shown). Evidence of variation was seen when comparing the above measures for the same agents across different cancer sites. The k, Se, and Sp for the receipt of paclitaxel and carboplatin were higher among patient treated for NSCLC as compared with those treated for ovarian cancer. Figure 2 illustrates how the use of multiple postdiagnosis periods changes the Se and Sp estimates for specific chemotherapeutic agents used to treat individuals diagnosed with stage II and III CRC in 2005. Generally, the Se for specific treatments reach their maximum close to the 8-month post-diagnosis period, with the exception of oxaliplatin for which Se continues to climb up to the 12-month postdiagnosis period. The Se of capecitabine is approximately 50% lower than the Se for all other CRC agents and remains steady over time. The Sp of Medicare claims for identifying patients who did not receive specific CRC chemotherapy agents was >93% for all postdiagnosis periods.
We conducted a sensitivity analysis to assess the impact that potential misclassification of the gold standard (ie, the POC studies) could have on our results, using the specific example of oxaliplatin treatment for CRC patients in 2005. We identified 10 individuals diagnosed with CRC in 2005 who had 2 or more claims for oxaliplatin during the 12month postdiagnosis, but were not identified by POC as having received oxaliplatin as part of the initial course of treatment. Because physicians would not likely submit claims to Medicare for administering oxaliplatin (an expensive treatment) unless it was actually delivered, we assumed that these patients were misclassified by the POC studies. We varied the percentage of oxaliplatin-treated patients that were missed by the 2005 CRC POC study from 0% to 60% (or 0 to 6 individuals) and assessed the changes in Se, Sp, and PPV. Over the range of values, the PPV increased the most from 84% to 94%, whereas the Se and Sp remained nearly constant, increasing only from 89% to 90% and 96% to 98%, respectively (data not shown).
DISCUSSION
We found that utilizing 6, 8, 10, or 12 months of Medicare claims after a primary diagnosis of in situ or earlystage breast, stage II or III CRC, non-small-cell lung, or ovarian cancer can accurately identify whether an individual received any chemotherapy as part of their initial course of treatment. However, the ability of Medicare claims to identify the receipt of specific chemotherapeutic agents seemed to vary by the agent, cancer site, and mode of administration. Medicare claims used to identify intravenously administered agents for CRC and NSCLC generally had a high Se, Sp, PPV, and NPV; although the Se tended to increase using longer postdiagnosis periods for more recently approved agents (ie, oxaliplatin). The Se and Sp estimates for identifying any chemotherapy treatment among individuals diagnosed with breast and ovarian cancers were generally lower than those for CRC and NSCLC. Across cancer sites, Medicare claims performed best when identifying specific agents used to treat NSCLC (i.e., carboplatin and paclitaxel) with all measures of agreement and validity exceeding 90%.
Our findings update a prior study by Warren et al 32 utilizing POC data (1991 32 utilizing POC data ( , 1995 32 utilizing POC data ( , and 1996 to assess the utility of Medicare claims data for identifying the receipt of chemotherapy among individuals diagnosed with in situ or early-stage breast, stage II or III CRC, and ovarian cancer. We found remarkably similar k and Se estimates for identifying the receipt of any chemotherapy across cancer sites, with all CIs encompassing the prior study estimates. However, our k and Se estimates of Medicare claims for identifying specific chemotherapeutic agents are higher than those reported by Warren and colleagues. For example, in our study the Se of claims to identify the receipt of cyclophosphamide for the treatment of ovarian cancer was 75% (Table 3 ) compared with only 47% in the earlier study. It is possible that coding and reporting behavior improved over time, especially with the rising cost of chemotherapy. 42 These updated measures further confirm the utility of Medicare claims to identify these agents and provide the relevant information that may be used to correct for misclassification.
Our study extended the Warren study by examining the chemotherapeutic agents that were not included in the original study, such as doxorubicin for breast cancer, oxaliplatin and capecitabine for CRC, and paclitaxel for breast and NSCLC. Another study examined the validity of Medicare claims for identifying specific agents in comparison to 2 different clinical trials among breast (1995 to 1997) and lung (1998 to 2000) cancer patients. The study reported the Se and Sp for doxorubicin as 91% (95% CI, 79%-98%) and 100%, and for paclitaxel as 86% (95% CI, 79%-92%) and 100%, consistent with our findings. 29 This is the first study to examine the validity of Medicare claims to identify oxaliplatin for individuals diagnosed with stages II and III CRC. The Se of Medicare claims to identify oxaliplatin increases with the length of the claims window postdiagnosis. A temporary HCPCS code was available for oxaliplatin (C9205) in 2005, while starting January 1, 2006, a permanent HCPCS code (J9263) was established. It is possible that physician coding improved after the permanent code was available, leading to better capture of oxaliplatin in later postdiagnosis periods. There have been no prior validation studies examining the reporting of capecitabine in the Medicare data. We observed consistently low Se estimates for capecitabine in the Medicare claims for all postdiagnosis periods. One possible explanation for its poor Se is that patients who cannot afford their copayments received the drug through pharmacy assistance programs sponsored by the pharmaceutical company. It may also be that patients had prescription drug insurance that covered oral medications and the patient or the provider did not submit a claim for capecitabine to Medicare. Capecitabine is covered under Medicare Part B, as it is an oral alternative to an intravenous medication (5-fluorouracil). Chemotherapeutic agents that are only in oral form would be covered under Medicare's part D prescription drug coverage, which was implemented in 2006. Using part D data to identify use of oral chemotherapies is limited as only 52% of Medicare beneficiaries have part D enrollment. 43 Our findings, taken together with limited part D enrollment among Medicare beneficiaries suggest that the reporting of oral chemotherapeutic agents in the Medicare data may be incomplete. However, additional validation of oral chemotherapeutic agents in the Medicare data is required. Two possible approaches to further explore the frequency of capecitabine claims in the outpatient drug setting would be to link: (1) Medicare dually eligible individuals to their Medicaid prescription drug claims; or (2) poor, elderly individuals that meet state pharmacy assistance program thresholds to their outpatient drug claims. These 2 groups are particularly unique and therefore results from these analyses may not be generalizable to the larger Medicare population. This study has a number of strengths. Through cooperation with the NCI and SEER registries, we linked verified treatment data obtained through physician confirmation or unified medical record review to Medicare claims for a large number of individuals aged Z65 years and diagnosed with 1 of 4 different cancers. The detailed POC data collection allowed us to assess the validity of Medicare claims to identify specific agents that have not previously been validated. We examined and reported variation in measures of validity across different postdiagnosis periods, whereas prior studies primarily used 1 or 2 broad postdiagnosis time windows. 28, 31, 32 Our study is not without limitations. There may be patients in the study who received treatment from another health care payer (eg, the Veterans Health Administration). These claims would not be captured in this analysis. Therefore, our results may be viewed as minimum thresholds that could be improved by combining information from other payers. Furthermore, approximately 26% of individuals in the POC studies lacked physician confirmation or unified medical record review and were therefore excluded from analysis. We also excluded individuals who had any health maintenance organization enrollment during the postdiagnosis periods, as detailed claims data were not reported to Medicare for these individuals. These exclusions along with our focus on individuals 65+ years limit the overall generalizability of our findings. This analysis examined the receipt of chemotherapy as part of the initial course of treatment, but did not distinguish between adjuvant and neoadjuvant treatment; however, we would not expect results to differ based on the receipt of therapy before or after surgery. Similarly, we cannot be sure that claims appearing later in the postdiagnosis period still relate to the initial course of treatment, or whether they are actually linked to treatment of recurrent or progressive cancer.
In conclusion, we assessed the utility of Medicare claims to identify the receipt of any chemotherapy and specific agents. Generally, Medicare claims can accurately identify the receipt of any chemotherapy and most specific agents administered intravenously. Medicare claims in combination with clinical data from cancer registries may be a valuable resource for health services research focused on evaluating treatment-related issues. In addition, these results may be useful to assess the potential impact of treatment misclassification in future studies. 
